- $2.10m
- $3.72m
- $1.41m
- 53
- 79
- 85
- 84
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.93 | ||
| PEG Ratio (f) | 0.01 | ||
| EPS Growth (f) | 300% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.15 | ||
| EV to EBITDA | 16.11 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | 4.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.12 | 1.41 | 1.24 | 1.41 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +300 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
QHSLab, Inc. is a medical device technology and software as a service (SaaS) company focused on primary care physicians (PCPs) and other healthcare providers to offer tools to evaluate and treat chronic diseases as well as provide preventive care through reimbursable procedures. Its Quality Health System Lab Expert System (QHSLab), a digital healthcare platform, provides clinical decision support and point of care solutions and supports non-face-to-face remote patient and therapeutic monitoring, to address chronic care and preventive medicine and is reimbursable to medical practice. It also markets and sells point-of-care, rapid-response diagnostic tests used in primary care practice. QHSLab offers a variety of digital healthcare intervention programs including allergies and asthma, mental health, musculoskeletal health and pain, hypertension, sleep disorders, weight loss and much more. The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- June 4th, 2021
- Public Since
- January 9th, 2002
- No. of Shareholders
- 650
- No. of Employees
- 4
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 11,281,527
- Address
- 901 Northpoint Parkway, Suite 302, WEST PALM BEACH, 33407
- Web
- https://www.usaqcorp.com/
- Phone
- +1 9293796503
- Auditors
- /s/ Accell Audit & Compliance, P.A.
Upcoming Events for USAQ
Similar to USAQ
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 22:49 UTC, shares in QHSLab are trading at $0.19. This share price information is delayed by 15 minutes.
Shares in QHSLab last closed at $0.19 and the price had moved by +55.71% over the past 365 days. In terms of relative price strength the QHSLab share price has outperformed the S&P500 Index by +44.39% over the past year.
The overall consensus recommendation for QHSLab is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreQHSLab does not currently pay a dividend.
QHSLab does not currently pay a dividend.
QHSLab does not currently pay a dividend.
To buy shares in QHSLab you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.19, shares in QHSLab had a market capitalisation of $2.10m.
Here are the trading details for QHSLab:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: USAQ
Based on an overall assessment of its quality, value and momentum QHSLab is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in QHSLab is $5.00. That is 2588.17% above the last closing price of $0.19.
Analysts covering QHSLab currently have a consensus Earnings Per Share (EPS) forecast of $0.05 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like QHSLab. Over the past six months, its share price has outperformed the S&P500 Index by +7.18%.
As of the last closing price of $0.19, shares in QHSLab were trading +5.45% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The QHSLab PE ratio based on its reported earnings over the past 12 months is 0.93. The shares last closed at $0.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
QHSLab's management team is headed by:
- Troy Grogan - CHM